New company investigates epigenetics of neurodegeneration

Juvenescence, a privately-held investment firm with a focus on increasing healthy human longevity, has announced the creation of a new biotech company to target the epigenetic underpinnings of neurodegeneration.

Souvien Therapeutics has been set up based on the research of Li-Huei Tsai, the director of The Picower Institute for Learning and Memory at Massachusetts Institute of Technology, and Stephen Haggarty, the director of the Chemical Neurobiology Laboratory at Harvard Medical School/Massachusetts General Hospital.

Professor Tsai said: “We have collected a substantial body of data implicating a critical epigenetic regulator of cellular aging in neurodegeneration. We are delighted to establish this new venture with Juvenescence and their experienced team of proven drug developers.”